A Phase 1 interventional study of Comparator: placebo and Comparator: Estrace in Postmenopause, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-16.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will develop a model for the assessment of successful activation/engagement of estrogen receptor beta using salivary biomarkers.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Comparator: placebo
Estrace 0.5 mg
Drug: Comparator: Estrace
Estrace 2 mg
Drug: Comparator: Estrace
placebo capsule once daily for 7 days.
Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
Also known as: Estrace
Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7
Subset of genes on the log ratio intensity scale from a microarray platform - signature was pre-specified from an internally conducted study in knock-out mice treated with estrogens- quantified as a ratio of up regulated versus down regulated genes
Time frame: Baseline and Day 7
Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.
Change from baseline in unstimulated labial gland saliva flow rate at Day 7
Time frame: Baseline and Day 7
This was a randomized, double-blind, placebo-controlled parallel group study in healthy postmenopausal women. Enrollment occurred from May 2008 through October 2008 across two US Phase I clinical research centers.
| Milestone | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo |
|---|---|---|---|
| Started | 10 | 6 | 11 |
| Completed | 9 | 6 | 11 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 0 | 0 |
Subset of genes on the log ratio intensity scale from a microarray platform - signature was pre-specified from an internally conducted study in knock-out mice treated with estrogens- quantified as a ratio of up regulated versus down regulated genes
| Fold change | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo |
|---|---|---|---|
| Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 | 0.028 ± 0.036 | -0.011 ± 0.048 | 0.080 ± 0.039 |
Change from baseline in unstimulated labial gland saliva flow rate at Day 7
| μL/min | 17β-estradiol 2.0 Milligrams | Placebo |
|---|---|---|
| Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7. | -0.26 (-0.65 to 0.13) | -0.64 (-1.00 to -0.28) |
Collected over AEs were collected from the time the subject signed the consent form until 14 days following the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 17β-estradiol 2.0 Milligrams | — | 0/10 (0%) | 8/10 (80%) |
| 17β-estradiol 0.5 Milligrams | — | 0/6 (0%) | 4/6 (66.7%) |
| Placebo | — | 0/11 (0%) | 7/11 (63.6%) |
| Event | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 3/10 | 1/6 | 2/11 |
| Lip PainGastrointestinal disorders | 2/10 | 1/6 | 3/11 |
| Lip SwellingGastrointestinal disorders | 0/10 | 0/6 | 2/11 |
| PalpitationsCardiac disorders | 0/10 | 1/6 | 0/11 |
| Chest DiscomfortGeneral disorders | 0/10 | 1/6 | 0/11 |
| Tongue BitingNervous system disorders | 0/10 | 1/6 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/6 | 0/11 |
| Stomach DiscomfortGastrointestinal disorders | 1/10 | 0/6 | 0/11 |
| Joint InjuryInjury, poisoning and procedural complications | 1/10 | 0/6 | 0/11 |
| Procedural Site ReactionInjury, poisoning and procedural complications | 1/10 | 0/6 | 0/11 |
| Age, Continuous(years) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Mean | 54.3 ± 5.0 | 53.8 ± 4.4 | 54.4 ± 4.8 | 54.2 ± 4.6 |
| Sex: Female, Male(Participants) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Female | 10 | 6 | 11 | 27 |
| Male | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | 17β-estradiol 2.0 Milligrams | 17β-estradiol 0.5 Milligrams | Placebo | Total |
|---|---|---|---|---|
| Mean | 29.1 ± 6.1 | 28.7 ± 3.2 | 29.2 ± 4.8 | 29.0 ± 4.9 |
No study locations are listed for this record.
The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol